Shire finally gets Baxalta to the deal-talks table

Shire CEO Flemming Ornskov

Shire ($SHPG) is reportedly one step closer to achieving its dream of nabbing Baxalta ($BXLT) to become a global rare-disease leader. The two companies are in takeover talks, Bloomberg reported Friday, with the Illinois pharma looking for a sweetened bid with a cash component. The way Shire sees it, a combined company could generate $20 billion in sales by 2020, with as many as 30 new drugs rolling out over the next 5 years, CEO Flemming Ornskov has said. More from FiercePharma

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.